Clinical Trial Update: ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer [Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 2 study of Galunisertib (LY2157299) in rectal adenocarcinoma; the study is active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Adenocarcinoma

Drugs mentioned

• Galunisertib (galunisertib)

Snippet

Sponsor: Providence Health & Services | Conditions: Rectal Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING